Deven Choksey Research has issued a BUY recommendation for Granules India Limited, setting a 12-month target of Rs 612 from the current market price of Rs 527, implying a potential upside of 16.2%.
Granules India announced on Tuesday that its US subsidiary, Granules Pharmaceuticals, Inc (GPI), has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug
KRChoksey Research has reaffirmed its "BUY" call on Granules India Ltd, targeting a price of Rs 700, which presents an upside potential of 22.4% from its current market price (CMP) of Rs 572.
Market expert Mitesh Thakkar has suggested two BUY Calls and two SELL Calls for today’s trading session. Indian markets are expected to open flat today and we can witness a range-bound session.
